Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept treat-and-extend for macular oedema due to central retinal vein occlusion
ACTRN12615000417583Phase 3Completed
- Sponsor
- Centre for Eye Research Australia
- Start
- May 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of aflibercept in central retinal vein occlusion (CRVO) and cystoid macular edema (CME), sponsored by Centre for Eye Research Australia. Primary endpoint: Mean change in best-corrected visual acuity from baseline. Started May 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
central retinal vein occlusion (CRVO)cystoid macular edema (CME)
Beyond the preview
Go deeper on ACTRN12615000417583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000417583.